PDSB · PDS Biotechnology Corporation

Summary

PDS Biotechnology Corporation updated its corporate presentation deck on April 24, 2026, filed as Exhibit 99.1, highlighting clinical data and pipeline progress for its Versamune platform.

Key takeaways

• Updated corporate presentation deck filed as Exhibit 99.1 on April 24, 2026.
• PDS0101 + pembrolizumab showed 77.4% disease control rate and 39.3 months median OS in 1L R/M HNSCC VERSATILE-002 trial.
• VERSATILE-003 Phase 3 pivotal trial ongoing with FDA-aligned PFS interim primary endpoint.
• Pipeline includes PDS01ADC in multiple Phase 2 trials for prostate, liver, and colorectal cancers.
• Upcoming catalysts include VERSATILE-003 interim PFS in 2Q 2026 and other data readouts in 2026-2027.